How Is Heparin Made? Inside the Natural and Synthetic Process

Most of the world’s heparin, one of the oldest and most widely used anticoagulant drugs, starts its life inside the intestines of slaughtered pigs. The mucosa lining porcine small intestines is rich in mast cells that naturally produce heparin, and scraping that tissue off is the first step in a long manufacturing chain that eventually yields pharmaceutical-grade material. The process is surprisingly low-tech at its origins and strikingly vulnerable to disruption, which has pushed researchers toward synthetic and bioengineered alternatives that are gradually becoming viable.

Where Heparin Comes From in the Body

Heparin belongs to a family of complex sugar chains called glycosaminoglycans. In mammals, it is produced almost exclusively by mast cells, a type of immune cell scattered throughout connective tissue. Inside mast cells, heparin forms a scaffold within storage granules, helping to package and stabilize other molecules like histamine and specialized enzymes called proteases.¹ A closely related molecule, heparan sulfate, shows up in virtually every cell type in the body, but heparin itself is confined to mast cells. This distinction matters for manufacturing: you cannot harvest heparin from just any tissue. You need organs where mast cells are densely packed, and the intestinal mucosa of pigs fits that requirement better than almost anything else.

Heparin’s medical value comes from the way it interacts with a blood protein called antithrombin. By binding to antithrombin through a specific five-sugar sequence, heparin dramatically accelerates the protein’s ability to shut down clotting enzymes like thrombin and factor Xa.² That mechanism is what makes heparin indispensable during surgeries, dialysis, and the treatment of blood clots.

From Slaughterhouse to Crude Heparin

Heparin production begins in the meatpacking industry, and it is tightly linked to sausage-casing manufacturing. After a pig is slaughtered, its small intestine is emptied and soaked in a salt solution. The inner lining, the mucosa, is then scraped off the intestinal wall, yielding roughly 0.8 kilograms of mucosa per animal. The emptied casings continue on to the sausage industry, and the mucosa is collected separately for heparin processing.³ In some operations, whole intestines are ground up instead of being scraped, a product called “hashed porcine guts.”

The mucosa degrades quickly. Sulfate groups that are critical for heparin’s anticoagulant activity can be lost during storage, so the raw material has to be preserved almost immediately. Sodium bisulfite, at concentrations of about 1.5 to 2.5 percent by weight, is the most common preservative. It works as an oxygen scavenger, limiting microbial growth and slowing the chemical changes that would reduce the final product’s potency.³

To extract crude heparin from this preserved mucosa, the tissue is treated with an alkaline protease solution that breaks down the proteins and frees the heparin molecules. The crude heparin is then captured using anion-exchange resins, which exploit heparin’s strong negative charge, or precipitated out of solution with quaternary ammonium salts.⁴ What you get at the end of this stage is crude heparin, a brownish material with variable purity that still needs significant refinement before it can go into a vial.

The Scale of the Supply Chain

The resource intensity of heparin production is striking. A lifecycle analysis found that producing a single metric ton of pharmaceutical heparin sodium requires about 437 tons of pig small intestine, sourced from the equivalent of nearly 30,000 tons of live swine. The extraction process consumes roughly 5,973 tons of water and generates over 5,700 tons of wastewater. About 1,608 tons of salt are used across various processing stages.⁵ Ethanol is recycled in a recovery loop, but volatile organic compounds still escape into the atmosphere. This is a high-input, low-yield industry, which helps explain why disruptions to the pig supply ripple so forcefully through global healthcare.

Why the World Depends on Chinese Pigs

China is the world’s largest pork producer, and Chinese companies manufacture the majority of both unfractionated heparin and low-molecular-weight heparin sold globally. The raw material supply is concentrated in one animal species from one country, a vulnerability that has already caused a catastrophe. In 2008, a viral disease reduced China’s pig herd and caused a sudden shortage of heparin raw material. That shortage opened the door to adulteration of heparin supplies with a cheap substitute called oversulfated chondroitin sulfate, which led to about 80 deaths and hundreds of severe allergic reactions worldwide.⁶

The threat has not gone away. When African Swine Fever began devastating Chinese pig herds in 2018, researchers raised alarms about a repeat of the 2008 scenario.⁶ The disease killed millions of pigs and tightened the raw material supply. These repeated crises have made diversifying heparin’s source one of the urgent priorities in pharmaceutical manufacturing.

The 2008 Contamination Crisis in Detail

The contaminant identified in the 2008 crisis, oversulfated chondroitin sulfate (OSCS), was a semi-synthetic substance that mimicked heparin’s chemical signature well enough to pass standard quality tests at the time. Research published in the New England Journal of Medicine showed that OSCS directly activated two inflammatory cascades in human blood: the kinin-kallikrein pathway, which generates bradykinin and causes blood pressure to drop, and the complement system, which produces compounds that trigger severe allergic-type reactions. These two pathways turned out to be linked, both depending on activation of a clotting factor called factor XII.⁷

Testing of contaminated samples revealed just how much OSCS had been introduced. One analytical method using capillary electrophoresis found that a contaminated raw heparin sample contained nearly 39 percent OSCS, and a formulated product tested at a similar level.⁸ That is not a trace impurity. It is roughly four parts contaminant for every six parts heparin, which underscored that the adulteration was deliberate, not accidental.

How Quality Testing Has Changed

The contamination crisis forced a major overhaul in how heparin is tested. Before 2008, standard pharmacopeial tests could not reliably distinguish OSCS from heparin because both are highly sulfated polysaccharides that behave similarly in basic assays. Since then, a range of more sensitive analytical methods have been developed or adapted for heparin screening. These include NMR spectroscopy, which can detect the unique chemical fingerprints of contaminants even when they are hidden beneath heparin’s dominant signals.⁹

Chromatographic methods have also been refined. One approach uses weak anion exchange chromatography coupled with online NMR detection, allowing analysts to separate and structurally identify individual impurities in a single run.¹⁰ The broader goal has been to build what researchers describe as an arsenal of complementary techniques, so that no single type of contaminant can slip through undetected again.¹¹

Making Low-Molecular-Weight Heparin

Standard unfractionated heparin is a mix of long sugar chains of varying sizes. Low-molecular-weight heparins (LMWHs) are derived from unfractionated heparin by breaking those chains into shorter fragments, which behave more predictably in the body. Different branded LMWHs, like enoxaparin and dalteparin, are each made by a different fragmentation method, and the choice of method gives each product a slightly different molecular profile.

The established approaches include chemical cleavage with nitrous acid, chemical beta-elimination, peroxidative cleavage, and enzymatic beta-elimination. These all use fairly aggressive chemistry, and one downside is that the strong reaction conditions can damage sugar units in the heparin backbone, altering the final product in unintended ways.¹² Research into gentler methods, including a photochemical approach that uses ultraviolet light to break the chains, has shown promise. In one study, a photolytic LMWH retained 96 percent of the sulfate groups from the starting heparin and showed anticoagulant activity comparable to enoxaparin and dalteparin.¹²

Bovine Heparin as a Backup Source

One way to reduce dependence on Chinese pigs is to use cattle as a heparin source. Bovine mucosal heparin (BMH) was actually used clinically before fears of mad cow disease pushed the market toward porcine material in the 1990s. Interest has revived. A comparative study found that bovine heparin has a slightly higher average molecular weight than porcine heparin, around 20 kilodaltons versus about 17.5, and lower anti-Xa potency, roughly 130 units per milligram compared to 185 for porcine material.¹³ When dosed to the same standard potency, though, bovine heparin performed comparably in anticoagulant assays. Several countries, particularly in South America where cattle are abundant and religious restrictions limit porcine product use, have been working to bring bovine heparin back into clinical use.

Fully Synthetic Heparin and Fondaparinux

The only fully synthetic heparin-related drug on the market is fondaparinux, a short five-sugar molecule that replicates the exact segment of heparin responsible for binding to antithrombin.¹⁴ It works, and it eliminates the pig-tissue dependency entirely, but the synthesis is extraordinarily difficult. One published route required 36 steps for the longest linear sequence and achieved an overall yield of just 0.017 percent from the starting sugar.¹⁵ That is not a misprint. For every million grams of starting material, you get roughly 170 grams of product.

Researchers have been working to bring that number up. More efficient routes using one-pot reaction strategies, where multiple chemical steps happen in a single vessel without isolating intermediates, have been developed to reduce the total number of steps and improve scalability.¹⁶ Even with those advances, fondaparinux remains expensive to make. And because it is only a five-sugar fragment, it cannot fully substitute for unfractionated heparin or LMWHs in all clinical scenarios; it activates factor Xa inhibition but lacks the longer chains needed for some of heparin’s other anticoagulant and biological activities.

Chemoenzymatic and Bioengineered Heparin

The most promising route to a non-animal heparin that matches the full complexity of the natural product is chemoenzymatic synthesis. This approach uses the same types of enzymes that mast cells use to build heparin, but deploys them in a controlled laboratory or industrial setting. Recombinant versions of the biosynthetic enzymes are combined with sugar-nucleotide building blocks to assemble heparin chains step by step, and researchers have demonstrated the synthesis of ultra-low-molecular-weight, low-molecular-weight, and full-length bioengineered heparin using this strategy.¹⁷

A key milestone was the report of a scalable process for producing bioengineered heparin that is biologically and compositionally similar to the standard porcine product as defined by the United States Pharmacopeia. The process starts with a tailored precursor molecule called N-sulfoheparosan, which is modified by immobilized biosynthetic enzymes on a solid support.¹⁸ The immobilization step is a practical detail with major implications: it means the enzymes can potentially be reused across batches, which brings costs down.

Another frontier involves engineering living cells to produce heparin directly. Chinese hamster ovary (CHO) cells, the workhorse of the biopharmaceutical industry, have been genetically modified to overexpress key enzymes in the heparin biosynthetic pathway. Early versions of these engineered cells produced material with low anticoagulant activity, but further genetic modifications boosted that activity roughly 100-fold.¹⁹ The product still does not match pharmaceutical heparin, but the trajectory of improvement has been encouraging.

Non-Mammalian Sources Under Investigation

Researchers have also explored whether heparin-like molecules can be harvested from marine organisms. A study of the bivalve mollusc Amussium pleuronectus isolated a low-molecular-weight glycosaminoglycan with a sulfation pattern resembling porcine heparan sulfate and an anticoagulant activity of about 95 international units per milligram.²⁰ That is well below the potency of pharmaceutical porcine heparin, but the finding demonstrated that marine invertebrates can produce structurally relevant molecules. Whether molluscs or other marine organisms could ever be farmed at a scale that matters for global heparin supply remains an open question, and a skeptical one at that.

How Heparin Is Reversed in the Clinic

Because heparin carries a strong negative charge, it can be neutralized by positively charged molecules. Protamine sulfate, a protein derived from fish sperm, is the standard reversal agent used during and after surgery. Protamine works by binding directly to heparin and pulling it away from antithrombin, forming an inactive complex that effectively switches off the anticoagulant effect.²¹ The mechanism is essentially electrostatic: protamine’s positive charges match up with heparin’s negative sulfate groups. Platelet factor 4, a natural protein released by activated platelets, neutralizes heparin through a similar charge-based mechanism.²² This reversibility is one of unfractionated heparin’s clinical advantages over some newer anticoagulants: when bleeding becomes a concern, the drug can be turned off quickly.

Beyond Blood Thinning

Heparin’s medical identity is almost entirely defined by anticoagulation, but the molecule has a wider biological repertoire that researchers are increasingly interested in exploiting. Studies have identified anti-inflammatory, antiviral, and anticancer properties. During the COVID-19 pandemic, heparin attracted attention as a potential therapeutic because it can bind to the spike protein used by SARS-CoV-2 to enter cells, acting as a kind of decoy that traps the virus before it reaches its target.²³

The catch is that heparin’s anticoagulant effect limits how much you can give a patient for these other purposes. Too high a dose and bleeding risk becomes unacceptable. This has driven interest in modified forms called non-anticoagulant heparins (NAHs), which are chemically altered to strip out the antithrombin-binding activity while preserving anti-inflammatory and antiviral effects. These modified molecules interact with proteins like P-selectin and heparanase, which are involved in inflammation and cancer metastasis.²⁴ If non-anticoagulant heparins prove clinically useful at scale, they would add a whole new category of demand on top of the already strained supply chain, making the push toward synthetic and bioengineered production even more urgent.